SG11202009981RA - Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof - Google Patents
Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereofInfo
- Publication number
- SG11202009981RA SG11202009981RA SG11202009981RA SG11202009981RA SG11202009981RA SG 11202009981R A SG11202009981R A SG 11202009981RA SG 11202009981R A SG11202009981R A SG 11202009981RA SG 11202009981R A SG11202009981R A SG 11202009981RA SG 11202009981R A SG11202009981R A SG 11202009981RA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- receptor antagonist
- solid forms
- glucocorticoid receptor
- glucocorticoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862656249P | 2018-04-11 | 2018-04-11 | |
PCT/US2019/027062 WO2019200156A1 (en) | 2018-04-11 | 2019-04-11 | Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009981RA true SG11202009981RA (en) | 2020-11-27 |
Family
ID=68162995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009981RA SG11202009981RA (en) | 2018-04-11 | 2019-04-11 | Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210147472A1 (en) |
EP (1) | EP3773515A4 (en) |
JP (1) | JP2021518842A (en) |
KR (1) | KR20210000719A (en) |
CN (1) | CN112272552A (en) |
AU (1) | AU2019252561A1 (en) |
CA (1) | CA3095042A1 (en) |
SG (1) | SG11202009981RA (en) |
TW (1) | TW202010502A (en) |
WO (1) | WO2019200156A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
CN108713023B (en) | 2015-12-23 | 2021-10-26 | 欧瑞克制药公司 | Glucocorticoid receptor inhibitors |
EP3394078A4 (en) | 2015-12-23 | 2019-11-27 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
PL3523315T3 (en) | 2016-10-07 | 2021-10-18 | Oric Pharmaceuticals, Inc. | Inhibitor of glucocorticoid receptor |
MX2024003254A (en) * | 2021-09-16 | 2024-04-03 | Corcept Therapeutics Inc | Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers. |
US12109272B2 (en) | 2021-09-16 | 2024-10-08 | Corcept Therapeutics Incorporated | Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4018167A1 (en) * | 1990-06-01 | 1991-12-05 | Schering Ag | METHOD FOR PRODUCING 10 (BETA) -H STEROIDS |
DE4042007A1 (en) * | 1990-12-22 | 1992-06-25 | Schering Ag | 6,7-MODIFIED-11 (BETA) -ARYL-4-ESTRENE |
CN108713023B (en) * | 2015-12-23 | 2021-10-26 | 欧瑞克制药公司 | Glucocorticoid receptor inhibitors |
PL3523315T3 (en) * | 2016-10-07 | 2021-10-18 | Oric Pharmaceuticals, Inc. | Inhibitor of glucocorticoid receptor |
-
2019
- 2019-04-11 WO PCT/US2019/027062 patent/WO2019200156A1/en unknown
- 2019-04-11 CA CA3095042A patent/CA3095042A1/en active Pending
- 2019-04-11 US US17/045,413 patent/US20210147472A1/en not_active Abandoned
- 2019-04-11 KR KR1020207031487A patent/KR20210000719A/en unknown
- 2019-04-11 EP EP19784556.3A patent/EP3773515A4/en not_active Withdrawn
- 2019-04-11 AU AU2019252561A patent/AU2019252561A1/en not_active Abandoned
- 2019-04-11 TW TW108112749A patent/TW202010502A/en unknown
- 2019-04-11 CN CN201980039674.3A patent/CN112272552A/en active Pending
- 2019-04-11 SG SG11202009981RA patent/SG11202009981RA/en unknown
- 2019-04-11 JP JP2020549737A patent/JP2021518842A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021518842A (en) | 2021-08-05 |
EP3773515A1 (en) | 2021-02-17 |
EP3773515A4 (en) | 2022-03-23 |
CA3095042A1 (en) | 2019-10-17 |
KR20210000719A (en) | 2021-01-05 |
AU2019252561A1 (en) | 2020-11-26 |
CN112272552A (en) | 2021-01-26 |
TW202010502A (en) | 2020-03-16 |
US20210147472A1 (en) | 2021-05-20 |
WO2019200156A1 (en) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202009981RA (en) | Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof | |
ZA201808623B (en) | Glucocorticoid receptor agonist and immunoconjugates thereof | |
ZA202003325B (en) | Glucocorticoid receptor agonist and immunoconjugates thereof | |
IL283362A (en) | Thrβ receptor agonist compound and preparation method and use thereof | |
IL281475A (en) | Farnesoid x receptor agonists and uses thereof | |
SG11202103609YA (en) | T-cell receptors and uses thereof | |
EP3826990A4 (en) | Compounds as neurokinin-1 receptor antagonists and uses thereof | |
IL281471A (en) | Farnesoid x receptor agonists and uses thereof | |
EP3594221A4 (en) | Gpr84 receptor antagonist and use thereof | |
IL277144A (en) | Adenosine receptor antagonists and uses thereof | |
IL281474A (en) | Farnesoid x receptor agonists and uses thereof | |
EP3628005A4 (en) | Corticotropin releasing factor receptor antagonists | |
EP3630763A4 (en) | Corticotropin releasing factor receptor antagonists | |
EP3419599A4 (en) | Il-6 antagonist formulations and uses thereof | |
IL292692A (en) | Mrgprx2 antagonists and uses thereof | |
EP3445769A4 (en) | Thyroid hormone receptor agonist and use thereof | |
EP3384920A4 (en) | Agonist of spexin-based galanin type 2 receptor and use thereof | |
HK1258622A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
EP3406614A4 (en) | Opioid receptor antagonist conjugate and use thereof | |
IL292693A (en) | Mrgprx2 antagonists and uses thereof | |
SG11202106401UA (en) | Estrogen receptor antagonist | |
EP3760620A4 (en) | Receptor antagonist, pharmaceutical composition comprising same, and usage thereof | |
IL283199A (en) | Stable glucocorticoid formulation | |
GB201816605D0 (en) | New formulations and uses thereof |